Evidence map›Paper›PMID 40777401›Full record

ArticlebioRxiv : the preprint server for biology2025

Human iPSC derived alveolar macrophages reveal macrophage subtype specific functions of itaconate in

Adam Krebs, Tomi Lazarov, Anthony Reynolds, Kimberly A Dill-McFarland, Abigail Xie, James Bean, Muxue Du, Olivier Levy, John Buglino, Aaron Zhong and 12 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Adam KrebsImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tomi LazarovImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6312-0080
Anthony ReynoldsDepartment of Medicine, University of Washington, Seattle, WA.
Kimberly A Dill-McFarlandDepartment of Medicine, University of Washington, Seattle, WA.
Abigail XieCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.
James BeanImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Muxue DuImmunology and Microbial Pathogenesis Program, Weill Cornell Medicine, New York, NY, USA.
Olivier LevyImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
John BuglinoImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aaron ZhongThe SKI Stem Cell Research Facility, The Center for Stem Cell Biology and Developmental Biology Program, Sloan-Kettering Institute.
Anna-Lena NeehusRockefeller University.
Stephanie Boisson-DupuisRockefeller University.
Jean-Laurent CasanovaRockefeller University.
Elouise E KroonSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-8551-3301
Marlo MöllerSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-0805-6741
Thomas R HawnDepartment of Medicine, University of Washington, Seattle, WA.
Ting ZhouThe SKI Stem Cell Research Facility, The Center for Stem Cell Biology and Developmental Biology Program, Sloan-Kettering Institute.
Lydia W S FinleyCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.ORCID 0000-0003-4023-7574
Marc Antoine Jean JusteGHESKIO Center, Port Au Prince, Haiti.
Dan FitzgeraldCenter for Global Health, Weill Cornell Medicine.
Frederic GeissmannImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael S GlickmanImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7918-5164

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
RESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDREJ SALI · 2018 to 2026
$21.4M
Pharmacology & ImmunoPathology (PIP) CoreU19AI162568 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE, GLICKMAN, MICHAEL S · 2021 to 2025
$13.0M
Human genetics of TB resistance in HIV-infected personsR01AI124349 · NIAID · MCGILL UNIVERSITY HEALTH CTR RES INST · PI SCHURR, ERWIN · 2016 to 2020
$8.0M
Weill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6M
NCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI124349NIAID NIH HHS U19 AI135990NIAID NIH HHS U19 AI162568NIGMS NIH HHS T32 GM152349
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40777401
PMCPMC12330731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.